It can vary based on things like inflation, manufacturer policies, and even the pharmacy location
The term has emerged in media coverage and online communities as a label for retatrutide, a nextgeneration injectable designed to activate three different hormone receptors involved in metabolism: GLP1 (glucagonlike peptide1) GIP (glucosedependent insulinotropic polypeptide) Glucagon The logic behind the nickname is simple: Older drugs such as semaglutide (Ozempic, Wegovy) mainly target GLP1 (single agonist)
In relation to the risk of developing cancer, a study published in The Journal of Clinical Endocrinology & Metabolism found no significant association between the dose of rhGH, mortality, and cancer incidence, making causality far less likely: Safety concerns have been raised regarding premature mortality, diabetes, neoplasia, and cerebrovascular disease in association with GH therapy
It is often included in routines focused on physical performance, mental clarity, and overall energy metabolism